Trial Profile
Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ART in LAP
- Sponsors Specialised Therapeutics Australia
- 31 May 2020 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 23 Jul 2018 Planned number of patients changed from 30 to 15.